Chase Corporation through its Resin Designs division announces the promotion of AXIS 151-091, a 2-part, UV-gellable adhesive with a chemical cure mechanism. AXIS 151-091 is the most recent addition to the AXIS line of medical assembly adhesives, all of which have been designed and fully tested to meet ISO 10993-5 cytotoxicity standards.

For medical device assembly, AXIS 151-091 offers the following:

Chase Corporation through its Resin Designs business has announced the successful development and certification of the AXIS line of medical assembly adhesives. AXIS 1064, and all AXIS adhesives, have been designed and fully tested to meet ISO 10993-5 cytotoxicity standards.